...
首页> 外文期刊>Tumour biology : >MicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact
【24h】

MicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact

机译:MicroRNA-21与microRNA-34:在计算机和体外分析的肺癌促进和抑制性microRNA及其临床影响

获取原文

摘要

MicroRNAs are well-known strong RNA regulators modulating whole functional units in complex signaling networks. Regarding clinical application, they have potential as biomarkers for prognosis, diagnosis, and therapy. In this review, we focus on two microRNAs centrally involved in lung cancer progression. MicroRNA-21 promotes and microRNA-34 inhibits cancer progression. We elucidate here involved pathways and imbed these antagonistic microRNAs in a network of interactions, stressing their cancer microRNA biology, followed by experimental and bioinformatics analysis of such microRNAs and their targets. This background is then illuminated from a clinical perspective on microRNA-21 and microRNA-34 as general examples for the complex microRNA biology in lung cancer and its diagnostic value. Moreover, we discuss the immense potential that microRNAs such as microRNA-21 and microRNA-34 imply by their broad regulatory effects. These should be explored for novel therapeutic strategies in the clinic.
机译:MicroRNA是众所周知的强RNA调节剂,可调节复杂信号网络中的整个功能单元。关于临床应用,它们具有作为预后,诊断和治疗的生物标志物的潜力。在这篇综述中,我们关注于两个主要参与肺癌进展的微小RNA。 MicroRNA-21促进和microRNA-34抑制癌症进展。我们在这里阐明涉及的途径,并将这些拮抗性microRNA嵌入相互作用网络中,强调其癌症microRNA生物学特性,然后对此类microRNA及其靶标进行实验和生物信息学分析。然后从microRNA-21和microRNA-34的临床角度阐明这一背景,作为肺癌中复杂的microRNA生物学及其诊断价值的一般示例。此外,我们讨论了诸如microRNA-21和microRNA-34之类的microRNA具有广泛的调节作用所蕴含的巨大潜力。这些应该在临床上探索新的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号